The 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 – a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes.
Those companies accounted for more than a quarter of the record $457.3 million spent on lobbying last year across the pharmaceut...
Upon closer examination, this analysis reveals patterns of influence peddling by the pharmaceutical industry in U.S. politics (ARC-0107 Influence Peddling). The massive spending on lobbying and campaign contributions suggests an effort to shape policies that favor the interests of pharmaceutical companies over those of patients, consumers, and taxpayers (ARC-0059 Lobbyocracy).
The lack of transparency in drug pricing negotiations between manufacturers and insurers raises concerns about hidden pr...